No pharmacokinetic or pharmacodynamic interaction between atorvastatin and the oral direct thrombin inhibitor ximelagatran

Journal of Clinical Pharmacology

Volumn 44, Issue 8, 2004, Pages 928-934

  Sarich, Troy C ^a   Schützer, Kajs Marie ^b   Dorani, Hassan ^b   Wall, Ulrika ^b   Kalies, Inge ^b   Ohlsson, Lis ^b   Eriksson, Ulf G ^b  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Atorvastatin; Drug interactions; Oral direct thrombin inhibitors; Thromboembolic disease; Ximelagatran

Indexed keywords

ATORVASTATIN; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MELAGATRAN; THROMBIN INHIBITOR; XIMELAGATRAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; GASTROENTERITIS; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; OPEN STUDY; PARTIAL THROMBOPLASTIN TIME; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADMINISTRATION, ORAL; ADULT; ANTICHOLESTEREMIC AGENTS; ANTICOAGULANTS; AREA UNDER CURVE; AZETIDINES; BENZYLAMINES; CROSS-OVER STUDIES; DRUG COMBINATIONS; DRUG INTERACTIONS; FEMALE; GLYCINE; HALF-LIFE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PARTIAL THROMBOPLASTIN TIME; PRODRUGS; PYRROLES;

EID: 3242742755     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004268047     Document Type: Article

References (22)

1. Eriksson UG, Bredberg U, Gislén K, Johansson LC, Frison L, Ahnoff M, et al: Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur J Clin Pharmacol 2003;59:35-43.
2. Eriksson UG, Bredberg U, Hoffmann KJ, Thuresson A, Gabrielsson M, Ericsson H, et al: Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2003;31:294-305.
3. Gustafsson D, Elg M: The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb Res 2003;109:S9-S15.
4. Wolzt M, Wollbratt M, Svensson M, Wahlander K, Grind M, Eriksson UG: Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects. Eur J Clin Pharmacol 2003;59:537-543.
5. Grind M, Hamren B, Baathe S, Wollbratt M, Eriksson UG: Pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation receiving long-term treatment: a population analysis by nonlinear mixed effect modeling [abstract MPI-99]. Clin Pharmacol Ther 2002;71:P31.
6. Bredberg E, Andersson TB, Frison L, Thuresson A, Johansson S, Eriksson-Lepkowska M, et al: Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions. Clin Pharmacokinet 2003;42:765-777.
7. Schulman S, Wåhlander K, Lundström T, Billing Clason S, Eriksson H, for the THRIVE III Investigators: Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003;349:1713-1721.
8. Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, et al for the EXULT A Study Group: Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003;349:1703-1712.
9. Eriksson BI, Bergqvist D, Kalebo P, Dahl OE, Lindbratt S, Bylock A, et al: Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002;360:1441-1447.
10. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Mouret P, Rosencher N, et al on behalf of the METHRO III Study Group: Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO III study. Thromb Haemost 2003;89:288-296.
11. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Lassen MR, Mouret P, et al, on behalf of the EXPRESS Study Group: The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 2003;1:2490-2496.
12. Olsson SB and Executive Steering Committee on behalf of the SPORTIF III Investigators: Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003;362:1691-1698.
13. Charatan F: US spending on prescription drugs rose by 19% in 2000. BMJ 2001;322:1198.
14. Williams D, Feely J: Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002;41:343-370.
15. Jacobsen W, Kuhn B, Soldner A, Kirchner G, Sewing K-F, Kollman PA, et al: Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-coa reductase inhibitor atorvastatin. Drug Metab Disp 2000;28:1369-1378.
16. Huisman MV, on behalf of the THRIVE Treatment Study Investigators: Efficacy and safety of the oral direct thrombin inhibitor ximelagatran for acute deep vein thrombosis with or without pulmonary embolism [abstract OC003]. Paper presented at the XIX Congress of the International Society on Thrombosis and Haemostasis, Birmingham, UK, July 12-18, 2003.
17. Lennernäs H: Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 2003;42:1141-1160.
18. Cilla DD Jr, Whitfield LR, Gibson DM, Sedman AJ, Posvar EL: Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin Pharmacol Ther 1996;60:687-695.
19. Larsson M, Logren U, Ahnoff M, Lindmark B, Abrahamsson P, Svennberg H, et al: Determination of melagatran, a novel direct thrombin inhibitor, in human plasma and urine by liquid chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl 2002;766:47-55.
20. Alberts AW, Chen J, Kuron G, Hunt V, Huff J, Hoffman C, et al: Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA 1980;77:3957-3961.
21. Sarich T, Johansson S, Schützer K-M, Wall U, Kessler E, Teng R, et al: The pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor, are unaffected by a single dose of alcohol. J Clin Pharmacol 2004;44:388-393.
22. Omar MA, Wilson JP: An FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002;36:288-295.